North America Newborn Screening Market (2025-2035) – Type, Application, Technology, Channel and Country Growth Outlook
The North America Newborn Screening Market plays a crucial role in early detection and management of numerous congenital disorders among newborns. Screening encompasses a wide range of laboratory and point-of-care tests designed to diagnose genetic, metabolic, and hearing-related conditions at birth. With increased focus on public health, advanced technology integration, and government mandates, the newborn screening sector in North America is experiencing rapid modernization and expansion. The growing birth rate and rising awareness about the importance of early diagnosis are driving demand for hospital, laboratory, and specialty center-based screening services across the region.
Latest Market Dynamics
Key Drivers
Rising prevalence of congenital disorders and mandatory government regulations across the US and Canada are driving hospitals and laboratories to boost screening volumes. In 2024, PerkinElmer Inc.
expanded its reagent kit offerings to meet regulatory inclusions for Cystic Fibrosis and Sickle Cell Disease screening.
Increased integration of advanced technologies like tandem mass spectrometry and next-gen sequencing is enabling faster and more accurate detection. Thermo Fisher Scientific Inc. launched automated mass spectrometry platforms in 2024, facilitating high-throughput newborn screening in major diagnostic centers.
Key Trends
Adoption of multiplex testing technologies is accelerating, allowing simultaneous screening for multiple metabolic and genetic disorders. Bio-Rad Laboratories Inc. introduced a multi-analyte panel in 2024 to streamline workflows and reduce sample-to-answer time for clinics.
Expansion of point-of-care screening, including pulse oximetry and portable hearing tests, is enhancing coverage in rural and community settings. Masimo Corporation announced a new generation of pulse oximeters in June 2024, optimized for neonatal accuracy.
Key Opportunities
Emergence of personalized medicine driven by genomics opens avenues for more comprehensive newborn genetic screening. Baebies Inc. collaborated with leading hospitals in early 2024 to implement advanced dried blood spot sequencing programs.
Cross-border screening initiatives and telehealth integrations are expanding reach in underserved regions, especially in Mexico. In July 2024, Medtronic Plc partnered with local government clinics to pilot digital screening programs.
Key Challenges
Complex reimbursement models and variations in insurance policies challenge universal adoption of newborn screening. Natus Medical Incorporated reported delayed expansions in some US states in July 2024 due to approval barriers.
Ensuring consistency and accuracy across decentralized testing sites remains a challenge amid rising demand, as demonstrated by regulatory alerts for data harmonization issued in May 2024, impacting smaller laboratories.
Key Restraints
High costs of implementing advanced technology platforms continue to restrain adoption in resource-limited clinics. Agilent Technologies Inc. highlighted budget constraints among smaller healthcare providers in its June 2024 market report.
Stringent regulatory approval timelines for new screening assays can delay market introduction and limit availability, with several suppliers experiencing product launch postponements in Q2 2024.
North America Newborn Screening Market Share by Type, 2025
Blood tests are projected to dominate the North America newborn screening market by type in 2025, owing to mandated programs and their effectiveness in early detection of a range of metabolic, genetic, and hematologic disorders. Hearing screening and pulse oximetry follow as key segments, driven by the increasing incidence of congenital hearing loss and cardiovascular conditions, respectively. The expansion of genetic testing and molecular techniques continues to bolster growth across all segments, reflecting ongoing investments in improved diagnostic accuracy.
North America Newborn Screening Market Share by Application, 2025
Dry blood spot screening maintains the highest market share by application in 2025, underpinned by its widespread use in the detection of multiple metabolic and genetic conditions from a single sample. Hearing screening secures the second-largest share due to expanded government mandates and hospital protocols, while diagnosis of cystic fibrosis and sickle cell disease continues to be prioritized. Critical congenital heart disease screening is also gaining momentum, supported by advancements in pulse oximetry and related technologies.
North America Newborn Screening Market Revenue (USD Million), 2020-2035
The North America newborn screening market is witnessing robust growth, with revenue increasing from 980 Million USD in 2020 to 1,370 Million USD in 2025, ultimately projected to reach 2,230 Million USD by 2035. This growth trajectory is attributed to increased test volumes, expanding screening panels, and greater public health investments. The upward trend underscores the region's commitment to improving neonatal health outcomes through early and comprehensive diagnostic programs, further supported by rapid technological innovation.
North America Newborn Screening Market YOY (%), 2020-2035
Annual year-over-year (YOY) growth in the North America newborn screening market is expected to range from 6.7% in 2020 to about 5.2% by 2035. While the early phase of expansion demonstrates rapid adoption due to policy changes and technology upgrades, growth rates gradually stabilize as the market matures and adoption reaches saturation in leading centers. Nevertheless, the consistent positive YOY indicates strong and ongoing investment in newborn health screening across the decade.
North America Newborn Screening Market Share by Country, 2025
The United States commands the majority market share for newborn screening in North America in 2025, reflecting its advanced healthcare infrastructure and extensive state-level screening mandates. Canada follows with a significant share attributable to nationalized health programs and innovation-driven pilot initiatives, while Mexico is emerging as a key market momentum through recent government investment and international collaborations aimed at improving neonatal outcomes across public health facilities.
North America Newborn Screening Market Player Share (%), 2025
In 2025, PerkinElmer Inc. remains the leading player in the North America newborn screening market, holding the highest share due to broad product offerings and established partnerships with public health agencies. Natus Medical Incorporated and Bio-Rad Laboratories Inc. maintain strong footprints through investments in technology and service expansion. The competitive landscape is characterized by continuous innovation, expanding portfolios, and collaborative approaches with hospitals and laboratories.
North America Newborn Screening Market Buyer Share (%), 2025
Hospitals represent the primary buyers within the North America newborn screening market in 2025 due to their role as central screening sites for most newborns. Diagnostic centers continue to expand their share, driven by technology upgrades and collaborations with public health authorities. Specialty centers, including genetics and cardiovascular clinics, are also emerging as important buyer segments, underscoring growing diversification in screening service delivery models.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
1370
Regions
United States, Canada, Mexico
Segments
Type, Application, Distribution Channels, Technology, Organization Size
June 2024: Masimo Corporation launched the Rad-97 pulse oximeter specifically designed for neonatal applications, enhancing accuracy and usability in newborn screening.
July 2024: Medtronic Plc announced a partnership with Mexican health authorities to roll out digital newborn screening and telehealth training in under-resourced clinics.
August 2024: PerkinElmer Inc. expanded its biochemical screening kits to include updated panels addressing recent regulatory mandates in the United States and Canada.
September 2024: Bio-Rad Laboratories Inc. introduced a high-throughput multiplex testing platform enabling combined metabolic and genetic disorder screening for hospital laboratories.
September 2024: Baebies Inc. initiated a collaboration with several US children’s hospitals to pilot the adoption of next-generation dried blood spot sequencing technology for personalized medicine approaches.
Frequently Asked Questions
About the Author
Clara
Senior Market Research Analyst
Clara is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Clara brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Clara has helped organizations translate data into actionable growth strategies.
